ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025
Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
purposePatients with extensive-stage small cell lung cancer are commonly treated with induction systemic therapy and consolidative thoracic radiotherapy (TRT). PARP inhibitors have demonstrated radiosensitization in preclinical lung cancer models. We performed an investigator-initiated, multi-institutional, single-arm, open-label phase I study of concurrent olaparib with TRT. PATIENTS AND
methodsPatients without progression after induction platinum/etoposide ± atezolizumab were treated with oral olaparib for 3 weeks and concurrent low-dose TRT (30 Gy/10 fractions) in weeks 2 and 3. Olaparib dose started at 50 mg twice daily and escalated in 50 mg/dose increments in cohorts of three patients each. Primary objectives were the safety and maximum tolerated dose (MTD) of olaparib + TRT. Secondary objectives included in-field local recurrence rate, progression-free survival, and overall survival.
resultsBetween October 2018 and March 2022, 24 patients with a median age of 68 years were treated (median follow-up, 11.4 months) with platinum/etoposide and 30 Gy/10 fractions TRT; 10 patients also received atezolizumab. The MTD of olaparib with TRT was 200 mg twice daily. There were three grade 3 (G3) dose-limiting adverse events (AE), including pneumonitis/pneumonia, esophagitis, and abdominal pain. The most common G2 to G3 treatment-related AE were esophagitis (n = 12) and pneumonitis/pneumonia (n = 2). There were no G4 or G5 AE. The 12-month cumulative incidence of local recurrence was 27%, and the median progression-free survival and overall survival were 3.6 and 17.7 months, respectively.
conclusionsThis study established the MTD and recommended a phase II dose of olaparib at 200 mg twice daily with concurrent low-dose TRT, and the combination seemed safe without unexpected toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.